Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?

Selenium is an essential trace element for humans, playing an important role in various major metabolic pathways. Selenium helps to protect the body from the poisonous effects of heavy metals and other harmful substances. Medical studies have provided evidence of selenium supplementation in preventi...

Full description

Saved in:
Bibliographic Details
Published in:Mutagenesis 2013-11, Vol.28 (6), p.625-629
Main Authors: Gupta, Satish, Jaworska-Bieniek, Katarzyna, Lubiński, Jan, Jakubowska, Anna
Format: Article
Language:English
Subjects:
Checkpoint Kinase 2 - genetics
Checkpoint Kinase 2 - metabolism
Dietary Supplements
Humans
Mutation
Neoplasms - enzymology
Neoplasms - genetics
Neoplasms - prevention & control
Selenium - administration & dosage
Selenium - physiology
Selenoproteins - metabolism
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Selenium is an essential trace element for humans, playing an important role in various major metabolic pathways. Selenium helps to protect the body from the poisonous effects of heavy metals and other harmful substances. Medical studies have provided evidence of selenium supplementation in preventing certain cancers. Low and too high selenium (Se) status correlates with increased risk of e.g. lung, larynx, colorectal and prostate cancers. A higher level of selenium and supplementation with selenium has been shown to be associated with substantially reduced cancer mortality. Selenium exerts its biological roles through selenoproteins, which are involved in oxidoreductions, redox signalling, antioxidant defence, thyroid hormone metabolism and immune responses. Checkpoint kinase 2 (CHEK2) is an important signal transducer of cellular responses to DNA damage and acts as a tumour suppressor gene. Mutations in the CHEK2 gene have been shown to be associated with increased risks of several cancers. Four common mutations in CHEK2 gene (1100delC, IVS2+1G>A, del5395 and I157T) have been identified in the Polish population. Studies have provided evidence that CHEK2-truncating and/or missense mutations are associated with increased risk of breast, prostate, thyroid, colon and kidney cancers. The variability in penetrance and cancer expression in CHEK2 mutation carriers can probably be explained by the influence of other genetic or environmental factors. One of the possible candidates is Se, which together with genetic variations in selenoprotein genes may influence susceptibility to cancer risk.
ISSN:0267-8357
1464-3804
DOI:10.1093/mutage/get050